Department of Obstetrics and Gynecology, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2020 Sep;83(9):812-816. doi: 10.1097/JCMA.0000000000000362.
The 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) is a pandemic disease worldwide. The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is continuing at a rapid speed. Till May 4, 2020, there have been 3,407,747 confirmed cases and 238,198 deaths globally. The common symptoms in pregnant women are fever, cough, and dyspnea. Angiotensin-converting enzyme 2 (ACE2) has transient overexpression and increased activity during pregnancy, which is now confirmed as the receptor of SARS-CoV-2 and plays essential roles in human infection and transmission. There is no evidence that pregnant women are more susceptible to SARS-CoV-2. To date, there is no valid medication or vaccination. The immune suppression or modulation during pregnancy increases the risk of severe pneumonia. Remdesivir is an antiviral medication targeting ribonucleic acid (RNA) synthesis that has clinical improvement in the treatment of SARS-CoV-2. Chloroquine is controversial in its effectiveness and safety to treat SARS-CoV-2. Remdesivir is safe in pregnancy. Chloroquine has not been formally assigned to a pregnancy category by the Food and Drug Administration (FDA). The management strategy includes monitoring fetal heart rate and uterine contractions; early oxygenation if O2 saturation is less than 95%; empiric antibiotics for prevention of secondary infection; corticosteroid to treat maternal SARS-CoV-2 disease routinely is not suggested, only for fetal lung maturation in selected cases; and consideration of delivery is according to the obstetric indication, gestational age, and severity of the disease. During epidemics, delivery at 32-34 weeks is considered. The indication for the Cesarean section should be flexible to minimize the risk of infection during the delivery. The newborn should be in isolation ward immediately after birth; breastfeeding is not contraindicated but should avoid direct transmission infection.
2019 年新型冠状病毒(2019-nCoV,后命名为 SARS-CoV-2)是一种全球大流行疾病。严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)的传播速度正在迅速加快。截至 2020 年 5 月 4 日,全球已确诊病例 3407747 例,死亡 238198 例。孕妇常见症状为发热、咳嗽和呼吸困难。血管紧张素转换酶 2(ACE2)在妊娠期间短暂过表达和活性增加,现已被证实为 SARS-CoV-2 的受体,在人类感染和传播中发挥重要作用。目前没有证据表明孕妇更容易感染 SARS-CoV-2。迄今为止,尚无有效的药物或疫苗。妊娠期间的免疫抑制或调节会增加患严重肺炎的风险。瑞德西韦是一种针对 RNA 合成的抗病毒药物,在治疗 SARS-CoV-2 方面具有临床改善作用。氯喹在治疗 SARS-CoV-2 的有效性和安全性方面存在争议。瑞德西韦在妊娠期间是安全的。氯喹尚未被美国食品和药物管理局(FDA)正式归类为妊娠用药。管理策略包括监测胎儿心率和子宫收缩;如果氧饱和度低于 95%,则早期给氧;经验性抗生素预防继发感染;不建议常规使用皮质类固醇治疗母亲的 SARS-CoV-2 疾病,仅在某些情况下用于胎儿肺成熟;根据产科指征、孕周和疾病严重程度考虑分娩。在流行期间,考虑在 32-34 周分娩。剖宫产的指征应灵活,以尽量减少分娩过程中的感染风险。新生儿出生后应立即隔离在病房内;母乳喂养无禁忌,但应避免直接传播感染。